• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Gross Motor Function in Individuals With SCN2A-Related Disorders: The Clinical Trial Readiness Study.SCN2A相关疾病患者的粗大运动功能:临床试验准备研究。
Neurol Clin Pract. 2025 Jun;15(3):e200479. doi: 10.1212/CPJ.0000000000200479. Epub 2025 May 2.
2
Assessing Communication Impairments in a Rare Neurodevelopmental Disorder: The Clinical Trials Readiness Study.评估一种罕见神经发育障碍中的沟通障碍:临床试验准备研究。
Neurol Clin Pract. 2025 Feb;15(1):e200391. doi: 10.1212/CPJ.0000000000200391. Epub 2024 Oct 18.
3
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
4
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
5
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
8
Prognosis of adults and children following a first unprovoked seizure.首次无诱因发作后成人和儿童的预后。
Cochrane Database Syst Rev. 2023 Jan 23;1(1):CD013847. doi: 10.1002/14651858.CD013847.pub2.
9
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
10
Nutritional interventions for survivors of childhood cancer.儿童癌症幸存者的营养干预措施。
Cochrane Database Syst Rev. 2016 Aug 22;2016(8):CD009678. doi: 10.1002/14651858.CD009678.pub2.

本文引用的文献

1
Assessing Communication Impairments in a Rare Neurodevelopmental Disorder: The Clinical Trials Readiness Study.评估一种罕见神经发育障碍中的沟通障碍:临床试验准备研究。
Neurol Clin Pract. 2025 Feb;15(1):e200391. doi: 10.1212/CPJ.0000000000200391. Epub 2024 Oct 18.
2
Framework for Multistakeholder Patient Registries in the Field of Rare Diseases: Focus on Neurogenetic Diseases.多利益相关方罕见病患者登记研究框架:以神经遗传疾病为例。
Neurology. 2024 Sep 24;103(6):e209743. doi: 10.1212/WNL.0000000000209743. Epub 2024 Aug 22.
3
Expanded clinical phenotype spectrum correlates with variant function in SCN2A-related disorders.SCN2A相关疾病中扩展的临床表型谱与变异功能相关。
Brain. 2024 Aug 1;147(8):2761-2774. doi: 10.1093/brain/awae125.
4
Caregiver perspectives on patient-focused drug development for Phelan-McDermid syndrome.照顾者对 Phelan-McDermid 综合征患者为中心的药物开发的看法。
Orphanet J Rare Dis. 2024 Mar 26;19(1):134. doi: 10.1186/s13023-024-03141-w.
5
Adaptive functioning and neurodevelopment in patients with Dravet syndrome: 12-month interim analysis of the BUTTERFLY observational study.Dravet综合征患者的适应性功能和神经发育:BUTTERFLY观察性研究的12个月中期分析
Epilepsy Behav. 2024 Feb;151:109604. doi: 10.1016/j.yebeh.2023.109604. Epub 2024 Jan 13.
6
FDA Patient-Focused Drug Development Guidances: Considerations for Trial Readiness in Rare Developmental and Epileptic Encephalopathies.FDA 患者为中心的药物开发指南:罕见发育性和癫痫性脑病临床试验准备的考虑因素。
Neurology. 2024 Jan 9;102(1):e207958. doi: 10.1212/WNL.0000000000207958. Epub 2023 Dec 15.
7
Top caregiver concerns in Rett syndrome and related disorders: data from the US natural history study.Rett 综合征及相关障碍的主要照护者关注点:来自美国自然史研究的数据。
J Neurodev Disord. 2023 Oct 13;15(1):33. doi: 10.1186/s11689-023-09502-z.
8
Comparing ability and norm-referenced scores as clinical trial outcomes for neurodevelopmental disabilities: a simulation study.比较能力和常模参照分数作为神经发育障碍临床试验结局的指标:一项模拟研究。
J Neurodev Disord. 2023 Jan 17;15(1):4. doi: 10.1186/s11689-022-09474-6.
9
Measuring the inch stones for progress: Gross motor function in the developmental and epileptic encephalopathies.衡量进展的里程碑:发育性和癫痫性脑病中的粗大运动功能
Epilepsy Behav. 2022 Dec;137(Pt A):108953. doi: 10.1016/j.yebeh.2022.108953. Epub 2022 Nov 9.
10
Evidence-Informed Milestones for Developmental Surveillance Tools.基于证据的发育监测工具里程碑。
Pediatrics. 2022 Mar 1;149(3). doi: 10.1542/peds.2021-052138.

SCN2A相关疾病患者的粗大运动功能:临床试验准备研究。

Gross Motor Function in Individuals With SCN2A-Related Disorders: The Clinical Trial Readiness Study.

作者信息

Berg Anne T, Kaat Aaron J, Paltell Katherine, Kaiser Ariela J E, Nili Amanda, Evans Lindsey, Anderson Erica L, Nesbitt Gerry, Myers Leah S

机构信息

FamilieSCN2A Foundation, Longmeadow, MA.

The Inchstone Project-Decoding Developmental Epilepsies, Washington DC.

出版信息

Neurol Clin Pract. 2025 Jun;15(3):e200479. doi: 10.1212/CPJ.0000000000200479. Epub 2025 May 2.

DOI:10.1212/CPJ.0000000000200479
PMID:40336930
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12054743/
Abstract

BACKGROUND AND OBJECTIVES

SCN2A-related disorders (RDs) are genetic conditions characterized by severe to profound impairments in multiple domains including gross motor function, which could serve as a nonseizure outcome in precision medicine therapy trials. This study evaluated specific properties of the Vineland Adaptive Behavior Scales-3 (VABS3) and other motor assessments for their fitness for use in trials of SCN2A-RDs.

METHODS

Sixty-five families recruited through the FamileSCN2A foundation enrolled their affected children ("participants," 28 female, median age 6.4 years, interquartile range [IQR] 4.1-10.5) in a 1-year, longitudinal study. Assessments were administered at 0 (study entry), 6, and 12 months. Assessments included the VABS3, Adaptive Behavior Assessment System 0-5 years (ABAS), a modified Functional Mobility Scale (FMS), and the Functional Activities Questionnaire-Walking Level (FAQ-WL).

RESULTS

The VABS3 composite score (34 [IQR 26-46]) indicated overall adaptive function >4 SDs below the normative mean. Forty percent of participants aged 2 years or older required wheelchairs for home distances, and 28% could not take any steps. The median standardized scores (SSs) for the VABS3 motor domain (20 [IQR 20-32]) and gross motor subdomain (1 [IQR 1-2]) reflected performance at the floor of the measures. Standardized motor scores discriminated poorly among participants with different levels of mobility (FAQ-WL and FMS) and different markers of diseases severity (presence of epilepsy, history of epileptic spasms, number of seizure medications). Cross-sectionally, SSs declined with increasing age. By contrast, raw scores of the VABS3 and ABAS and growth scale values (GSVs) of the VABS3 had relatively little floor effects. They distinguished well between participants based on FAQ-WL and FMS scores and between those with different disease severity markers. Test-retest and inter-rater reliability for all scores were excellent. No motor score changed significantly over time in the longitudinal analyses.

DISCUSSION

Gross motor function in people with SCN2A-RDs is so severely impaired that it cannot be adequately measured with norm-referenced (standardized) scores. GSVs and alternative scoring assessments used out of their intended age range have superior and promising psychometric features in this severely impaired group, and they should be considered in future precision medicine trials for SCN2A-RDs and other similarly severe, rare disorders.

摘要

背景与目的

与SCN2A相关的疾病(RDs)是一种遗传性疾病,其特征是在多个领域存在严重至极重度的损害,包括粗大运动功能,这可作为精准医学治疗试验中的非癫痫性结局。本研究评估了文兰适应性行为量表第3版(VABS3)和其他运动评估方法在SCN2A-RDs试验中的适用性。

方法

通过FamileSCN2A基金会招募的65个家庭,让他们受影响的孩子(“参与者”,28名女性,中位年龄6.4岁,四分位间距[IQR]4.1 - 10.5)参加为期1年的纵向研究。在0(研究入组)、6个月和12个月时进行评估。评估包括VABS3、0 - 5岁适应性行为评估系统(ABAS)、改良的功能移动性量表(FMS)以及功能活动问卷 - 步行水平(FAQ-WL)。

结果

VABS3综合得分(34[IQR 26 - 46])表明总体适应性功能比正常均值低4个标准差以上。40%年龄在2岁及以上的参与者在家中出行需要轮椅,28%的参与者无法行走任何步数。VABS3运动领域的标准化得分中位数(SSs)(20[IQR 20 - 32])和粗大运动子领域的标准化得分中位数(1[IQR 1 - 2])反映了在测量下限的表现。标准化运动得分在不同移动水平(FAQ-WL和FMS)以及不同疾病严重程度标志物(癫痫的存在、癫痫痉挛病史、抗癫痫药物数量)的参与者之间区分能力较差。横断面分析中,SSs随年龄增长而下降。相比之下,VABS3和ABAS的原始得分以及VABS3的生长量表值(GSVs)地板效应相对较小。它们基于FAQ-WL和FMS得分以及不同疾病严重程度标志物,能很好地区分参与者。所有得分的重测信度和评分者间信度都非常好。在纵向分析中,没有运动得分随时间有显著变化。

讨论

SCN2A-RDs患者的粗大运动功能严重受损,以至于无法用常模参照(标准化)得分进行充分测量。在这个严重受损的群体中,超出其预期年龄范围使用的GSVs和替代评分评估具有更优越且有前景的心理测量特征,在未来针对SCN2A-RDs和其他类似严重、罕见疾病的精准医学试验中应予以考虑。